Papers
12
Total Citations
162
H-Index
8
About
Marc Zanaty is a urological surgeon and researcher whose work centers on prostate cancer treatment, particularly robot-assisted radical prostatectomy (RARP) and its oncological and functional outcomes. Based primarily within Canadian academic urology, Zanaty has made meaningful contributions to understanding how surgical timing, perioperative factors, and patient characteristics influence outcomes following minimally invasive prostate surgery. Among his most impactful contributions is his investigation into whether surgical delay affects biochemical recurrence and pathological outcomes after radical prostatectomy, providing evidence-based guidance for surgical scheduling decisions. His prospective cohort study of 322 men examining predictors of post-prostatectomy urinary incontinence — cited 31 times — has helped clinicians better counsel patients on continence recovery. He has also explored innovative biomarkers, demonstrating the prognostic utility of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in predicting biochemical recurrence. Notably, his work on testosterone replacement therapy in hypogonadal prostate cancer survivors addresses a clinically underexplored and sensitive area of survivorship care. With a cumulative citation record exceeding 150 across his most recognized works, Zanaty's research collectively advances the precision and safety of robotic prostate surgery, offering valuable clinical insights for urologists and patients navigating prostate cancer management.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10